Cardiometabolic News and Research

RSS

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

2 Jun 2010

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

Evotec AG today announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million.

19 May 2010

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

Atherotech Inc. will exhibit its VAP® Cholesterol Test in booth #102 at the National Lipid Association (NLA) Scientific Sessions 2010. The meeting takes place May 13-16 at the Sheraton Hotel and Towers in Chicago.

13 May 2010

GENFIT announces milestone as compound developed in partnership enters the clinic

GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the achievement of a milestone in the therapeutic research collaboration with one of its strategic pharmaceutical partners.

6 May 2010

Atherotech to showcase VAP Cholesterol Test at Internal Medicine 2010

Atherotech Inc. announced it will exhibit its VAP® Cholesterol Test in booth #1305 at Internal Medicine 2010, the annual scientific meeting of the American College of Physicians (ACP). The meeting takes place April 22-24, 2010, at the Metro Toronto Convention Centre in Toronto, Canada.

20 Apr 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.

1 Apr 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

Studies show association between high levels of vitamin D and decreased risk of heart disease

Middle aged and elderly people with high levels of vitamin D could reduce their chances of developing heart disease or diabetes by 43%, according to researchers at the University of Warwick.

16 Feb 2010

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.

28 Jan 2010

International congress reflects emerging importance of abdominal obesity

Clinical and basic science researchers from around the world will convene in Hong Kong from January 28 to 30 for the First International Congress on Abdominal Obesity: "Bridging the Gap between Cardiology and Diabetology."

28 Jan 2010

NicOx receives EMEA approval for naproxcinod MAA

NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.

22 Jan 2010

NicOx, TOPIGEN Pharmaceuticals terminate TPI 1020 collaboration

NicOx S.A. today announced that NicOx and TOPIGEN Pharmaceuticals Inc. have mutually terminated their collaboration for TPI 1020. This decision was made as a result of the acquisition of TOPIGEN by Pharmaxis announced yesterday.

12 Jan 2010

Arena Pharmaceuticals submits lorcaserin NDA to the FDA

Arena Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients.

22 Dec 2009

Women with gestational glucose intolerance at risk of metabolic syndrome

Women who have gestational glucose intolerance (a condition less severe than gestational diabetes) exhibit multiple cardiovascular risk factors as early as three months after birth, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

1 Dec 2009

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.

28 Oct 2009

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA.

28 Oct 2009

Football linemen at higher risk of future health problems

For today's athletes, size and strength can mean the difference between championships, scholarships and million-dollar paydays. But new research comparing the signs of metabolic syndrome in professional baseball and football players, presented at the American College of Gastroenterology's 74th Annual Scientific Meeting in San Diego, reveals that the larger professional athletes - specifically football linemen - may encounter future health problems despite their rigorous exercise routines.

27 Oct 2009

Athletes may face future health problems despite their rigorous exercise routines, says study

26 Oct 2009

Cardiometabolic News and Research

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

GENFIT announces milestone as compound developed in partnership enters the clinic

Atherotech to showcase VAP Cholesterol Test at Internal Medicine 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Studies show association between high levels of vitamin D and decreased risk of heart disease

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

International congress reflects emerging importance of abdominal obesity

NicOx receives EMEA approval for naproxcinod MAA

NicOx, TOPIGEN Pharmaceuticals terminate TPI 1020 collaboration

Arena Pharmaceuticals submits lorcaserin NDA to the FDA

Women with gestational glucose intolerance at risk of metabolic syndrome

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Football linemen at higher risk of future health problems

Athletes may face future health problems despite their rigorous exercise routines, says study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News